Close
CDMO Safety Testing 2026
Novotech

Drug Research

Signant Health Brings Its eConsent Solution to China for Large Neuroscience Study in Collaboration with Shanghai Mental Health Center

Signant Health (formerly CRF Health and Bracket), a leading patient-centric technology company, has been selected to provide electronic informed consent for a significant neuroscience study by the prestigious Shanghai Mental Health Center (SMHC). This landmark investigator-led Schizophrenia trial, which...

Bora secures FDA approval for CDMO services

Bora, a contract development and manufacturing organization (CDMO) that specializes in modified release (MR) and solvent production, has reported a successful FDA general inspection for its facility in Zhunan, Taiwan. The publicly listed company recently hosted the siteโ€™s fifth successful...

Particle analysis: Growing demand with biologics

The development and introduction of new biological drug substances has been on the rise, and so have the regulatory requirements placed on these often life-saving products. At the same time, innovative analytical technologies have been developed that offer new...

New calcium ingredient with improved flow and compactability properties

At this yearโ€™s CPhI Worldwide, mineral producer Omya will launch its new Calcipurยฎ DC range, which comprises seven different grades of high-purity, directly compressible and free-flowing Natural Calcium Carbonates. Thanks to improved processing properties, the ingredient is ideally suited...

Cancer Research UK and Hummingbird Bioscience join forces to advance novel antibody drug into clinical trials

Cancer Research UK, the worldโ€™s leading cancer charity, and Hummingbird Bioscience, an innovative systems-biology enabled biotechnology company, have announced a partnership to develop Hummingbirdโ€™s anti-HER3 antibody drug, HMBD-001, for the treatment of people with HER3 driven cancer. Under the terms...

Vesselon Acquires FDA-Approved Lipid Microsphere Drug Imagent For Therapeutic Platform

Vesselon, an oncology therapeutics company, announced the acquisition of an FDA-approved drug Imagentยฎ. Vesselon will use Imagent to create novel therapeutic complexes in four classes of cancer drugs: cytokines, oncolytic viruses, monoclonal antibodies, and nucleic acid constructs. Vesselon incorporates Imagent...

FDA Approves Daiichi Sankyos TURALIO pexidartinib for the Treatment of Select Patients with TGCT a Rare and Debilitating Tumor

Daiichi Sankyo Company, Limited announced that the U.S. FDA approved TURALIOโ„ข (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป